Start right here—with help from SareptAssist.

Need some guidance as you navigate the complexities of starting treatment? We’re here to help with SareptAssist, our patient support program.


It’s easy to enroll: Once your doctor has prescribed EXONDYS 51, just print out the START form and sign to indicate your consent. Then take it to your doctor so they can complete and send in the form for you. This authorizes SareptAssist to start working on your behalf.

SareptAssist is a resource available only to those who have been prescribed EXONDYS 51 (eteplirsen). SareptAssist is only available in the U.S.



Give us a call.


Case Managers are available Monday – Friday
8:30am – 6:30pm ET




Did you know? While your doctor is your primary resource for discussing your medical needs, your Case Manager can be one of your key contacts for questions regarding insurance benefits, treatment coordination, and access.



What to expect after your START form is submitted.

A welcome call.

Introducing you to SareptAssist.


When enrollment is complete, your dedicated Case Manager will call to welcome you to SareptAssist, explain how they can help, and answer your questions. With their experience in rare diseases, insurance plans, and healthcare networks, you’ll have Support, by your side™.

Benefits investigation.

Ensuring you’re covered for EXONDYS 51.


Your Case Manager will help you understand your insurance benefits and contact your insurance company to verify coverage. Depending on your type of insurance and relevant circumstances, they can also provide information on other financial assistance options you may be eligible for.



Desktop star

Sign up to get updates
from Sarepta.

There are a lot of steps; families and patients have lots of questions. It’s my responsibility to really just explain the whole process.”

–Sarah, SareptAssist Case Manager

Related FAQs

How can I connect with other families of children with Duchenne?

Several advocacy organizations offer Duchenne patients and families the opportunity to come together at events throughout the year. Find out more about Duchenne advocacy groups.



WHAT IS EXONDYS 51 (eteplirsen)?

EXONDYS 51 is used to treat Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation in the dystrophin gene that can be treated by skipping exon 51. EXONDYS 51 was approved under accelerated approval. Accelerated approval allows for drugs to be approved based on a marker that is considered reasonably likely to predict a clinical benefit. EXONDYS 51 treatment increased the marker, dystrophin, in skeletal muscle in some patients. Verification of a clinical benefit may be needed for EXONDYS 51 to continue to be approved.

Read More


Allergic reactions, including wheezing, chest pain, cough, rapid heart rate, and hives have occurred in patients who were treated with EXONDYS 51. Seek immediate medical care if signs and symptoms of allergic reactions occur.

Side effects that happened at least 25% more often in 8 patients treated with EXONDYS 51 by intravenous infusion than in 4 patients treated with an inactive intravenous infusion were problems with balance (38%, 0%), vomiting (38%, 0%), and skin irritation (25%, 0%). The most common side effects were problems with balance and vomiting.

The most common side effects seen in greater than 10% of patients receiving EXONDYS 51 (N=163) in other clinical trials were headache, cough, rash, and vomiting. 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782).

Please see the full Prescribing Information for EXONDYS 51 (eteplirsen).